The signature is present in 8% of TCGA (The Cancer Genome Atlas)-tumor samples while also being associated with a significantly higher mortality, suggesting that embryonic KRAS4B programs could be a focus of future anti-cancer stem cell drug investigations. The gene discussed is KRAS; the disease is cancer.